Blood Advances

Article	Citations
Smith CC, Levis MJ, Perl AE, et al. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022;6(7):2144-2155.	226
Abramson JS, Siddiqi T, Garcia J, et al. Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel–treated patients in the TRANSCEND NHL 001 trial. Blood Adv. 2021;5(6)	167
Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study	166
Addressing and overcoming disparities in GVHD	154
Predictors of liver disease outcomes in individuals with hemophilia and HCV infection	130
Converting IMPROVE bleeding and VTE risk assessment models into a fast-and-frugal decision tree for optimal hospital VTE prophylaxis	127
On a collision course: SARS-CoV-2 variants and CAR T cells	127
Campbell BA, Dobos G, Haider Z, et al. International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies. Blood Adv. 2023;7(21):	125
Kennedy VE, Wong C, Huang C-Y, et al. Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma. Blood Adv. 2021;5(23):5344-5348.	117
Pirillo C, Birch F, Tissot FS, et al. Metalloproteinase inhibition reduces AML growth, prevents stem cell loss, and improves chemotherapy effectiveness. Blood Adv. 2022;6(10):3126-3141.	115
Low neutralizing activity of AZD7442 against current SARS-CoV-2 Omicron variants in patients with B-cell malignancies	110
Complement C5 inhibition in early onset HELLP syndrome	107
Complete absence of GLUT1 does not impair human terminal erythroid differentiation	106
Pirfenidone for the treatment of bronchiolitis obliterans syndrome related to chronic graft-versus-host disease	102
COVID-19 vaccination during therapy in relation to COVID-19 death in CLL	100
Prognostic role of interim PET in follicular lymphoma: a post hoc study of FOLL12 trial by Fondazione Italiana Linfomi	98
Cortisol in sickle cell disease: a systematic review and meta-analysis	95
Characteristics and outcomes of patients with CLL and CDKN2A/B deletion by fluorescence in situ hybridization	94
Ibrutinib plus rituximab vs ibrutinib monotherapy in patients with Waldenström macroglobulinemia: a pooled analysis	93
Diagnostic Criteria for NK-Cell Large Granular Lymphocyte Leukemia: Validation Through a Multicentric International Study	91
Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea	87
Molecular subclusters of follicular lymphoma: a report from the United Kingdom’s Haematological Malignancy Research Network	84
Chimeric antigen receptor T-cell therapy in adults with B-cell acute lymphoblastic leukemia	84
Regional Brain Age is Decreased in Children with Sickle Cell Anemia	82
Targeting bone marrow mesenchymal stromal cell–derived IL-6 to overcome acute myeloid leukemia chemoresistance	81

Reduced FVIII recovery associated with anti-FVIII PEG antibodies after BNT162b2 SARS-CoV-2 vaccination	81
Transfusion therapy for sickle cell disease: what’s new?	76
Best but not perfect: indirect measure of low iron stores	75
ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis	75
Deep PIM kinase substrate profiling reveals new rational cotherapeutic strategies for acute myeloid leukemia	73
Selective modulation of activated protein C activities by a nonactive site–targeting nanobody library	73
The A-HIPI prediction model in advanced-stage Hodgkin lymphoma: identification of risk groups and creation of an online tool	71
Conditioning intensity and probability of live birth after blood or marrow transplantation, a BMTSS report	71
Genome editing of patient-derived iPSCs identifies a deep intronic variant causing aberrant splicing in hemophilia A	71
Cellular and humoral immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia	70
Sickle cell disease is a risk factor for transplant-associated thrombotic microangiopathy in children	70
Bite-size introduction to canine hematologic malignancies	70
Priapism before and after hematopoietic stem cell therapy in individuals with sickle cell disease	70
Clinical Trial Success Rate in Lymphoma: Fate of Trials and Agents from 2000 to 2019	70
The OHI index predicts early mortality from organ dysfunction and survival benefit from etoposide in patients with lymphoma	69
Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial	67
Treatment strategies and outcome in relapsed peripheral T-cell lymphoma: results from the Netherlands Cancer Registry	66
Steroid tapering after GVHD Rx: not too fast, not too slow	66
Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703	66
Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma	66
Genetic landscapes and curative effect of CAR T-cell immunotherapy in patients with relapsed or refractory DLBCL	64
A mouse model for hemoglobin SC disease recapitulates characteristic human pathologies	63
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML	63
Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years	62
Structural analysis of platelet fragments and extracellular vesicles produced by apheresis platelets during storage	62
CAR T cells targeting C-C motif chemokine receptor 4 (CCR4) selectively deplete human Tregs ex vivo and in vivo	61
ASCT vs CART for patients with relapsed LBCL in PR: role of TMTV	60
Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma	60
International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies	59
Applying CRISPR-Cas9 screens to dissect hematological malignancies	59
Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel	59
Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia	59
American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients	59
Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia	59
BCL11A promotes myeloid leukemogenesis by repressing PU.1 target genes	58
Mitigating T-cell mitochondrial dysfunction in CLL to augment CAR T-cell therapy: evaluation in an immunocompetent model	58
Outcomes with third-party virus-specific T cells after the use of single-antigen cell lines to predict HLA restriction	58
Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia	57
Infections and parameters of humoral immunity with talquetamab in relapsed/refractory multiple myeloma in MonumenTAL-1	57
Deletion of Y chromosome before allogeneic hematopoietic stem cell transplantation in male recipients with female donors	56
CD58 loss in tumor cells confers functional impairment of CAR T cells	56
Megakaryocyte/platelet-derived TGF-β1 inhibits megakaryopoiesis in bone marrow by regulating thrombopoietin production in liver	56
Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium	55
Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes	54
Desensitization to calaspargase pegol appears to be less successful than pegaspargase	54
Real world comparison of progression free survival and time to next therapy in 761 newly diagnosed multiple myeloma patients	54
Matrix stiffness controls megakaryocyte adhesion, fibronectin fibrillogenesis, and proplatelet formation through Itgβ3	54
Longitudinal clinical data improve survival prediction after hematopoietic cell transplantation using machine learning	54
LMWH prevents thromboinflammation in the placenta via HBEGF-AKT signaling	53
Improvements in health-related quality of life in patients with transfusion-dependent β-thalassemia after exagamglogene autotemcel	53

Glucagon-like peptide 1 receptor agonists and venous thromboembolism in type 2 diabetes: a target trial emulation	53
Pediatric adapted risk index to predict 2-year transplant-related mortality post-HSCT in children	53
Long-term data needed for SCD gene therapy	52
Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell–mediated tumor responses	52
Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the Fondazione Italiana Linfomi MCL0208 trial	52
Long-term survival with sickle cell disease: a nationwide cohort study of Medicare and Medicaid beneficiaries	52
Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma	51
Implementation of hospital-based sickle cell newborn screening and follow-up programs in Haiti	51
Return emergency department visits for recurrent pulmonary embolism symptoms in children and adolescents	51
Dasatinib-induced spleen contraction leads to transient lymphocytosis	51
ASH's Commitment to SCD: Building on 10 Years of Progress	51
Novel humanized loss-of-function NF1 mouse model of juvenile myelomonocytic leukemia	50
D-dimer for patients on VKA vs DOAC: impact on the validity of D-dimer to make decision for extended anticoagulation	50
Cumulative donor-specific antibody threshold predicts platelet transfusion response in HLA-alloimmunized patients	50
Uptake of long-chain fatty acids from the bone marrow suppresses CD8+ T-cell metabolism and function in multiple myeloma	50
Adaptation of Serious Illness Care Program to be delivered via telehealth for older patients with hematologic malignancy	50
Mutant PIK3CA is a targetable driver alteration in histiocytic neoplasms	49
U2AF1 and EZH2 mutations are associated with nonimmune hemolytic anemia in myelodysplastic syndromes	49
Genomic landscape of patients with germline RUNX1 variants and familial platelet disorder with myeloid malignancy	49
Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from the ASPEN study	49
Donor age contributes more to the rheological properties of stored red blood cells than donor sex and biological age distribution	49
Trends in volumes and survival after hematopoietic cell transplantation in racial/ethnic minorities	49
Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement: a GLA/DRST study	49
G3BP2-KIT drives leukemia amenable to kinase inhibition in Ph-like ALL	48
Interpretation of response in BOS: the definitions remain key	48
FBXW7β isoform drives transcriptional activation of the proinflammatory TNF cluster in human pro-B cells	48
High pulmonary hypertension risk by echocardiogram shortens survival in polycythemia vera	48
Can baseline cytomegalovirus IgG titers predict cytomegalovirus reactivation after ide-cel therapy?	48
Another step toward frontline BTK inhibitor therapy in MCL	48
Efficacy and safety of BCMA nanobody CAR T-cell therapy in relapsed or refractory plasma cell myeloma	48
Code status transitions in patients with high-risk acute myeloid leukemia	47
Evaluating complement dysregulation in livedoid vasculopathy using a functional assay	47
Horwitz SM, Scarisbrick JJ, Dummer R, et al. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician’s choice in cutaneous T-cell lymphoma: final data. Blood Adv. 2021;5(23):5098-5	47
Epigenetic features support the diagnosis of B-cell prolymphocytic leukemia and identify 2 clinicobiological subtypes	47
Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities	46
Myb drives B-cell neoplasms and myeloid malignancies in vivo	46
Distinguishing STAT3/STAT5B-mutated large granular lymphocyte leukemia from myeloid neoplasms by genetic profiling	46
Hasselbalch HC, Kristiansen MH, Kjær L, et al. CHIP-JAK2V617F, chronic inflammation, abnormal megakaryocyte morphology, organ failure, and multimorbidities. Blood Adv. 2024;8(3):681-682.	46
PD-1 inhibition for relapse after allogeneic transplantation in acute myeloid leukemia and myelodysplastic syndrome	46
Sustained hematologic remission after discontinuation of sutimlimab treatment in patients with cold agglutinin disease	45
An αIIbβ3 ligand-mimetic murine monoclonal antibody that produces platelet activation by engaging the FcγIIa receptor	45
Commentary on the ASH ISTH NHF WFH 2021 guidelines on the diagnosis of VWD: reflections based on recent contemporary test data	44
Impaired exercise capacity in post–COVID-19 syndrome: the role of VWF-ADAMTS13 axis	44
Opposing effects of KDM6A and JDP2 on glucocorticoid sensitivity in T-ALL	44
T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a phase 1 trial	44
Neighborhood socioeconomic status and overall survival among children with acute lymphoblastic leukemia	43
Ibrutinib increases miR-181a/b in leukemic cells from patients with chronic lymphocytic leukemia	43
High frequency of central nervous system involvement in transformed Waldenström macroglobulinemia	43
Cabozantinib and thromboembolism in patients with cancer: a systematic review, meta-analysis and retrospective study	43
Graft-versus-host disease may cause pulmonary restriction, but not all restriction is graft-versus-host disease	42
Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS	42
Association between hemoglobin values and VWF assays: a multicenter investigation	42
Outcomes of Radiation Integrated with T-cell-engaging Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma	42
Severe parvovirus B19 infection in patients with sickle cell disease hospitalized in intensive care units	42
Danazol treatment for telomere biology disorders: long-term results of a phase I/II study	42
Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience	42
Benefit of Rituximab Maintenance After First-line Bendamustine-Rituximab in Patients with Mantle Cell Lymphoma	42
Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease	41
Fanconi anemia neuroinflammatory syndrome: brain lesions and neurologic injury in Fanconi anemia	41
Antileukemic properties of the kinase inhibitor OTSSP167 in T-cell acute lymphoblastic leukemia	41
The ISHLT chronic lung allograft dysfunction consensus criteria are applicable to pulmonary chronic graft-versus-host disease	41
Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma	41
Genome-wide copy number profiling enhances risk stratification in multiple myeloma by shallow whole-genome sequencing	41
EMD originates from hyaluronan-induced homophilic interactions of CD44 variant-expressing MM cells under shear stress	41
Mitochondrial dsRNA from B-ALL cells stimulates mesenchymal stromal cells to become cancer-associated fibroblasts	40
A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease	40
Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia	40
AMPK drives both glycolytic and oxidative metabolism in murine and human T cells during graft-versus-host disease	40
RNA-regulatory exosome complex suppresses an apoptotic program to confer erythroid progenitor cell survival in vivo	39
Establishment of a predictive model for GVHD-free, relapse-free survival after allogeneic HSCT using ensemble learning	39
Factor XI inhibitors: a new class of anticoagulants	39
Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis	39
Long live the red blood cell: biotin tagging in SCD	39
Commentary on the 2021 ASH Guidelines on use of anticoagulation in patients with COVID-19 being discharged from the hospital	39
Cutaneous dysbiosis characterizes the post–allogeneic hematopoietic stem cell transplantation period	39
Transcriptomic analysis reveals proinflammatory signatures associated with acute myeloid leukemia progression	39
The American Society of Hematology Health Equity Compendium: examining health equity across the Blood journals	39
Bridging therapy before axi-cel for lymphoma	39
Presentation of CXCL12γ by heparan sulfate proteoglycans activates CXCR4 without desensitization in normal and malignant B cells	38
Should we move to a genomic classification of neutrophilic myeloid neoplasms?	38

HSCT using carrier donors for CD40L deficiency results in excellent immune function and higher CD40L expression in cTfh	38
Lineage switching of the cellular distribution of BRAF V600E in multisystem Langerhans cell histiocytosis	37
Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial	37
Thromboprophylaxis in hospitalized and nonhospitalized medical patients: what’s new?	37
Gioacchino E, Koyunlar C, Zink J, et al. Essential role for Gata2 in modulating lineage output from hematopoietic stem cells in zebrafish. Blood Adv. 2021;5(13):2687-2700.	37
KDIGO-defined kidney dysfunction predicts long-term outcomes in a multicenter cohort of adults with sickle cell disease	37
Long-term outcomes of chemoimmunotherapy with obinutuzumab/chlorambucil in chronic lymphocytic leukemia	37
Outpatient subcutaneous alemtuzumab is feasible and safe for aplastic anemia and is associated with high response rates	36
Analysis of immune responses in patients with CLL after heterologous COVID-19 vaccination	36
Feasibility of high-dose methotrexate administered on day 1 of (R)CHOP in aggressive non-Hodgkin lymphomas	36
Combinatorial targeting of epigenome-modifying enzymes with decitabine and RN-1 synergistically increases HbF	36
Cell-free DNA measurable residual disease as a predictor of postallogeneic hematopoietic cell transplant outcomes	36
Evaluation of allogeneic and autologous membrane-bound IL-21–expanded NK cells for chronic lymphocytic leukemia therapy	36
Cost-effectiveness of Voncento prophylaxis vs on-demand treatment in von Willebrand disease in the United Kingdom	36
Tumor-associated antigen–specific T cells with nivolumab are safe and persist in vivo in relapsed/refractory Hodgkin lymphoma	36
Infection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: real-world analysis from CIBMTR	36
Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912	36
Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy	36
T-cell malignancies with anti-CD19 chimeric antigen receptor T-cell therapy	36
Thyroid hormones contribute to JAK/STAT pathway abnormal activation, promoting T-cell lymphoma dissemination	36
Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma	36
Comments and concerns on the analysis of DAPS-ITP trial	36
To pursue gene therapy or not? Is it feasible after graft failure in allogeneic hematopoietic cell transplant recipients	36
Vemurafenib combined with cladribine and cytarabine results in durable remission of pediatric BRAF V600E–positive LCH	36
Genetically defined individual reference ranges for tryptase limit unnecessary procedures and unmask myeloid neoplasms	35
TP53-mutant myelodysplastic syndrome and acute myeloid leukemia: the black hole of hematology	35
Response to Danilov et al	35
JMML tumor cells disrupt normal hematopoietic stem cells by imposing inflammatory stress through overproduction of IL-1β	35
Dual ASXL1 and CSF3R mutations drive myeloid-biased stem cell expansion and enhance neutrophil differentiation	35
Landscape and clinicopathologic features of RAS pathway mutations in chronic myelomonocytic leukemia	35
Pilot study of an inpatient physical activity intervention for older adults treated intensively for acute myeloid leukemia	35
Population-scale Analysis Reveals Germline Loss of SERPING1 (C1-Inhibitor) is a Polyphenotypic Thrombotic Disorder	35
Familial Clusters and Clinical Features, Complications, and Outcomes in 1000 Patients with Waldenström Macroglobulinemia	35
A 69 long noncoding RNA signature predicts relapse and acts as independent prognostic factor in pediatric AML	35
Cellular and biochemical heterogeneity contributes to the phenotypic diversity of transfusion-dependent β-thalassemia	35
Is estimated exposure an accurate surrogate for measured fludarabine levels in patients with CAR T-cell therapy?	34
Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study	34
IgG testing, immunoglobulin replacement therapy, and infection outcomes in patients with CLL or NHL: real-world evidence	34
Eculizumab for refractory thrombosis in antiphospholipid syndrome	34
Immune profiling after allogeneic hematopoietic cell transplantation in pediatric acute myeloid leukemia	34
Utility or futility? A contemporary approach to allogeneic hematopoietic cell transplantation for TP53-mutated MDS/AML	34
Utilization Patterns of Hematology Consultation in the Intensive Care Unit: An 11-year Single Center Experience	34
Safety and efficacy of letetresgene autoleucel alone or with pembrolizumab for relapsed/refractory multiple myeloma	34
HLA reduction of human T cells facilitates generation of immunologically multicompatible cellular products	34
Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study	34
Deciphering the regulatory landscape of murine splenic response to anemic stress at single-cell resolution	34
Real-World Comparative Effectiveness of Bruton Tyrosine Kinase Inhibitors in Relapsed/Refractory Mantle Cell Lymphoma	33
Digital pathology in pediatric nodular lymphocyte-predominant Hodgkin lymphoma: correlation with treatment response	33
Interactions between integrin α9β1 and VCAM-1 promote neutrophil hyperactivation and mediate poststroke DVT	33
Circulating MRP8/14 drives faster platelet COX-1 recovery via MRP4 impairing the duration of aspirin response	33
Early response markers predict survival after etoposide-based therapy of hemophagocytic lymphohistiocytosis	33
Cytokine receptor IL27RA is an NF-κB–responsive gene involved in CD38 upregulation in multiple myeloma	33
Daratumumab for immune thrombotic thrombocytopenic purpura	33
Molecular profiling of primary renal diffuse large B-cell lymphoma unravels a proclivity for immune-privileged tropism	33
Low frequency of Vγ9Vδ2 T cells predicts poor survival in newly diagnosed acute myeloid leukemia	33
Role of race and ethnicity in survival among children/young adults with relapsed ALL: a Children’s Oncology Group report	33
A CD3 humanized mouse model unmasked unique features of T-cell responses to bispecific antibody treatment	33
Efficacy and safety of dapsone in adult primary immune thrombocytopenia	32
Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study	32
International consensus statement on the management of cardiovascular risk of Bruton’s tyrosine kinase inhibitors in CLL	32
Patient-specific MDS-RS iPSCs define the mis-spliced transcript repertoire and chromatin landscape of SF3B1-mutant HSPCs	32
Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma	32
Challenges and limitations of mobilization and stem cell collection for gene therapy of sickle cell disease	32
Allogeneic hematopoietic stem cell transplantation in patients with germ line DDX41 mutated myeloid malignancies	32
Effectiveness and safety of prophylactic anticoagulation among hospitalized patients with inflammatory bowel disease	32
Effect of rabbit ATG PK on outcomes after TCR-αβ/CD19–depleted pediatric haploidentical HCT for hematologic malignancy	32
Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group	32
Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma	31
PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma	31
Prognostic impact of patient-reported symptoms in multiple myeloma	31
Mass spectrometry-detected MGUS is associated with obesity and other novel modifiable risk factors in a high-risk population	31
Expanding donor options: haploidentical transplant recipients are also highly likely to have a 7/8-matched unrelated donor	31
Real-world treatment patterns and outcomes in patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab	31
The use of FDA-approved medications for preventing vaso-occlusive events in sickle cell disease	31
World Coalition on SCD launches, sparking global focus on SCD diagnosis and care	31
Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma	31
Alliance A061202: ixazomib, pomalidomide, and dexamethasone for patients with lenalidomide-refractory MM in first relapse	31
CD4+ CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapy	31
Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantation	31
Characteristics, primary treatment, and survival of MDS/MPN with neutrophilia: a population-based study	31
Risk of infectious adverse events of venetoclax therapy for hematologic malignancies: a systematic review and meta-analysis of RCTs	31
Clinical features, pathophysiology, and therapy of poor graft function post–allogeneic stem cell transplantation	31
Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD	30
Magrolimab plus rituximab in relapsed/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1/2 trial	30
Metabolically aberrant extracellular mitochondria induce oxidative endotheliopathy in traumatic brain injury	30
Inclusion, characteristics and reporting of older patients in recent registration trials for DLBCL: A systematic review	30
Tarlock K, Gerbing RB, Ries RE, et al. Prognostic impact of cooccurring mutations in FLT3-ITD pediatric acute myeloid leukemia. Blood Adv. 2024;8(9):2094-2103.	30
BCLAF1 restrains stress responses in hematopoietic stem cells to support expansion and repopulation	30
Histiocytosis of the orbit and its association with KRAS mutations	30
Identification of a Conformational Epitope on the E Antigen Implicated in Anti-E Alloimmunization	30
Peripheral neuropathy and BTKis in Waldenström: a response?	30
CAR T-cell therapy in mantle cell lymphoma with secondary CNS involvement: a multicenter experience	30
Whole genome sequences discriminate hereditary hemorrhagic telangiectasia phenotypes by non-HHT deleterious DNA variation	30
Role of NKG2D ligands and receptor in haploidentical related donor hematopoietic cell transplantation	30
Recombinant Erwinia asparaginase (JZP458) in ALL/LBL: complete follow-up of the Children’s Oncology Group AALL1931 study	30